Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2014, Article ID 168940, 13 pages
http://dx.doi.org/10.1155/2014/168940
Review Article

Ginseng and Anticancer Drug Combination to Improve Cancer Chemotherapy: A Critical Review

1Department of Pharmacy, Xiamen Medical College, Xiamen, Fujian 361008, China
2Center for Advancement of Drug Research and Evaluation, College of Pharmacy, Western University of Health Sciences, Pomona, CA 91766, USA
3Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, CA 91766, USA

Received 16 December 2013; Revised 17 March 2014; Accepted 20 March 2014; Published 30 April 2014

Academic Editor: Zhong Zuo

Copyright © 2014 Shihong Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. T. Che, Z. J. Wang, M. S. S. Chow, and C. W. K. Lam, “Herb-herb combination for therapeutic enhancement and advancement: theory, practice and future perspectives,” Molecules, vol. 18, pp. 5125–5141, 2013. View at Google Scholar
  2. Z. J. Wang, C. Xie, Y. Huang, C. W. K. Lam, and M. S. S. Chow, “Overcoming chemotherapy resistance with herbal medicines: past, present and future perspectives,” Phytochemistry Reviews, vol. 13, no. 1, pp. 323–337, 2014. View at Google Scholar
  3. F. Qi, A. Li, Y. Inagaki et al., “Chinese herbal medicines as adjuvant treatment during chemo- or radio-therapy for cancer,” BioScience Trends, vol. 4, no. 6, pp. 297–307, 2010. View at Google Scholar
  4. B. K. Vogler, M. H. Pittler, and E. Ernst, “The efficacy of ginseng. A systematic review of randomised clinical trials,” European Journal of Clinical Pharmacology, vol. 55, no. 8, pp. 567–575, 1999. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Lü, Q. Yao, and C. Chen, “Ginseng compounds: an update on their molecular mechanisms and medical applications,” Current Vascular Pharmacology, vol. 7, no. 3, pp. 293–302, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. A. T. Smolinski and J. J. Pestka, “Modulation of lipopolysaccharide-induced proinflammatory cytokine production in vitro and in vivo by the herbal constituents apigenin (chamomile), ginsenoside Rb1 (ginseng) and parthenolide (feverfew),” Food and Chemical Toxicology, vol. 41, no. 10, pp. 1381–1390, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Blumenthal, “Herb sales down 15 percent in mainstream market,” HerbalGram, no. 51, article 69, 2001. View at Google Scholar
  8. S. A. Nag, J. J. Qin, W. Wang, M. H. Wang, H. Wang, and R. Zhang, “Ginsenosides as anticancer agents: in vitro and in vivo activities, structure-activity relationships, and molecular mechanisms of action,” Frontiers in Pharmacology, vol. 3, no. 25, pp. 1–18, 2012. View at Google Scholar
  9. D. W. Kaufman, J. P. Kelly, L. Rosenberg, T. E. Anderson, and A. A. Mitchell, “Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey,” The Journal of the American Medical Association, vol. 287, no. 3, pp. 337–344, 2002. View at Google Scholar · View at Scopus
  10. T. Yun and S. Choi, “Preventive effect of ginseng intake against various human cancers: a case-control study on 1987 pairs,” Cancer Epidemiology Biomarkers and Prevention, vol. 4, no. 4, pp. 401–408, 1995. View at Google Scholar · View at Scopus
  11. T. Liu, Y. Huang, D. Cui et al., “Inhibitory effect of ginsenoside Rg3 combined with gemcitabine on angiogenesis and growth of lung cancer in mice,” BMC Cancer, vol. 9, article 250, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Q. Hua, X. K. Shen, S. K. Qin, and H. Y. Chen, “Anti-invasion and anti-metastasis effects of ginsenoside Rg3 on the hepatocellular carcinoma cell line,” Zhongguo Ai Zheng Za Zhi, vol. 15, no. 4, pp. 326–330, 2005. View at Google Scholar
  13. K. W. Leung, L. W. T. Cheung, Y. L. Pon et al., “Ginsenoside Rb1 inhibits tube-like structure formation of endothelial cells by regulating pigment epithelium-derived factor through the oestrogen β receptor,” British Journal of Pharmacology, vol. 152, no. 2, pp. 207–215, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Papapetropoulos, “A ginseng-derived oestrogen receptor β (ERβ) agonist, Rb1 ginsenoside, attenuates capillary morphogenesis,” British Journal of Pharmacology, vol. 152, no. 2, pp. 172–174, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. A. B. Fishbein, C. Wang, X. Li et al., “Asian ginseng enhances the anti-proliferative effect of 5-fluorouracil on human colorectal cancer: comparison between white and red ginseng,” Archives of Pharmacal Research, vol. 32, no. 4, pp. 505–513, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. C. X. Gu, J. P. Qiao, M. L. Zhu et al., “Preliminary evaluation of the interactions of Panax ginseng and Salvia miltiorrhiza Bunge with 5-fluorouracil on pharmacokinetics in rats and pharmacodynamics in human cells,” The American Journal of Chinese Medicine, vol. 41, no. 2, pp. 443–458, 2013. View at Google Scholar
  17. Y. S. Chang, E. Seo, C. Gyllenhaal, and K. I. Block, “Panax ginseng: a role in cancer therapy?” Integrative Cancer Therapies, vol. 2, no. 1, pp. 13–33, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. G. Du, C. Wang, Z. Zhang et al., “Caspase-mediated pro-apoptotic interaction of panaxadiol and irinotecan in human colorectal cancer cells,” Journal of Pharmacy and Pharmacology, vol. 64, no. 5, pp. 727–734, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. X. Li, C. Wang, S. R. Mehendale, S. Sun, Q. Wang, and C. Yuan, “Panaxadiol, a purified ginseng component, enhances the anti-cancer effects of 5-fluorouracil in human colorectal cancer cells,” Cancer Chemotherapy and Pharmacology, vol. 64, no. 6, pp. 1097–1104, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Matsunaga, M. Katano, T. Saita, H. Yamamoto, and M. Mori, “Potentiation of cytotoxicity of mitomycin C by a polyacetylenic alcohol, panaxytriol,” Cancer Chemotherapy and Pharmacology, vol. 33, no. 4, pp. 291–297, 1994. View at Publisher · View at Google Scholar · View at Scopus
  21. S. M. Kim, S. Y. Lee, D. Y. Yuk et al., “Inhibition of NF-κB by ginsenoside Rg3 enhances the susceptibility of colon cancer cells to docetaxel,” Archives of Pharmacal Research, vol. 32, no. 5, pp. 755–765, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. S. M. Kim, S. Y. Lee, J. S. Cho et al., “Combination of ginsenoside Rg3 with docetaxel enhances the susceptibility of prostate cancer cells via inhibition of NF-κB,” European Journal of Pharmacology, vol. 631, no. 1–3, pp. 1–9, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. R. Gao, J. Jin, and Y. Niu, “Potentiated effects of total saponins of Panax ginseng on inhibition of leukemic cells by cytotoxic drugs,” Zhongguo Zhong Xi Yi Jie He Za Zhi, vol. 19, no. 1, pp. 17–19, 1999. View at Google Scholar · View at Scopus
  24. S. H. Baek, X. L. Piao, U. J. Lee, H. Y. Kim, and J. H. Park, “Reduction of cisplatin-induced nephrotoxicity by ginsenosides isolated from processed ginseng in cultured renal tubular cells,” Biological and Pharmaceutical Bulletin, vol. 29, no. 10, pp. 2051–2055, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. T. Yokozawa and E. Dong, “Role of ginsenoside-Rd in cisplatin-induced renal injury: special reference to DNA fragmentation,” Nephron, vol. 89, no. 4, pp. 433–438, 2001. View at Publisher · View at Google Scholar · View at Scopus
  26. C. Choi, G. Kang, and Y. Min, “Reversal of P-glycoprotein-mediated multidrug resistance by protopanaxatriol ginsenosides from Korean red ginseng,” Planta Medica, vol. 69, no. 3, pp. 235–240, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. M. J. Shin, Y. S. Kim, Y. S. Kwak, Y. B. Song, Y. S. Kim, and J. D. Park, “Enhancement of antitumor effects of paclitaxel (taxol) in combination with red ginseng acidic polysaccharide (RGAP),” Planta Medica, vol. 70, no. 11, pp. 1033–1038, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Miao, Q. Liu, and Y. R. Liu, “Chemo-sensitivity enhancing effects of Shengai injection on various chemotherapeutic drugs,” Chinese Traditional and Herbal Drugs, vol. 44, no. 7, pp. 875–876, 2013. View at Google Scholar
  29. H. R. B. Raghavendran, S. Rekha, J. Shin et al., “Effects of Korean ginseng root extract on cisplatin-induced emesis in a rat-pica model,” Food and Chemical Toxicology, vol. 49, no. 1, pp. 215–221, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Kim, I. Yoon, B. Lee et al., “Effects of Korean red ginseng extract on cisplatin-induced nausea and vomiting,” Archives of Pharmacal Research, vol. 28, no. 6, pp. 680–684, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. X. F. Du, C. Z. Jiang, C. F. Wu, E. K. Won, and S. Y. Choung, “Synergistic immunostimulating activity of pidotimod and red ginseng acidic polysaccharide against cyclophosphamide-induced immunosuppression,” Archives of Pharmacal Research, vol. 31, no. 9, pp. 1153–1159, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. J. Y. Shim, Y. Han, J. Y. Ahn, Y. S. Yun, and J. Song, “Chemoprotective and adjuvant effects of immunomodulator ginsan in cyclophosphamide-treated normal and tumor bearing mice,” International Journal of Immunopathology and Pharmacology, vol. 20, no. 3, pp. 487–497, 2007. View at Google Scholar · View at Scopus
  33. W. Ni, X. Zhang, B. Wang et al., “Antitumor activities and immunomodulatory effects of ginseng neutral polysaccharides in combination with 5-fluorouracil,” Journal of Medicinal Food, vol. 13, no. 2, pp. 270–277, 2010. View at Google Scholar · View at Scopus
  34. T. Xu, Y. Xin, M. Cui, X. Jiang, and L. Gu, “Inhibitory effect of ginsenoside Rg3 combined with cyclophosphamide on growth and angiogenesis ovarian cancer,” Chinese Medical Journal, vol. 120, no. 7, pp. 584–588, 2007. View at Google Scholar · View at Scopus
  35. E. Ernst, “Panax ginseng: an overview of the clinical evidence,” Journal of Ginseng Research, vol. 34, no. 4, pp. 259–263, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. Q. Zhang, X. Kang, and W. Zhao, “Antiangiogenic effect of low-dose cyclophosphamide combined with ginsenoside Rg3 on Lewis lung carcinoma,” Biochemical and Biophysical Research Communications, vol. 342, no. 3, pp. 824–828, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. B. Kenarova, H. Neychev, C. Hadjiivanova, and V. D. Petkov, “Immunomodulating activity of ginsenoside Rg1 from Panax ginseng,” Japanese Journal of Pharmacology, vol. 54, no. 4, pp. 447–454, 1990. View at Google Scholar · View at Scopus
  38. Z. Chen, P. Wang, W. Huang, and L. Liu, “Experimental study on effects of shengmai injection: enhancing 5-FU anti-tumor efficacy and reducing its toxicity,” Journal of Chinese Integrative Medicine, vol. 3, no. 6, pp. 476–479, 2005. View at Google Scholar · View at Scopus
  39. M. Ge, Y. Y. Fang, G. P. Liu, and S. D. Guan, “Effect of Shengmai injection on diaphragmatic contractility in doxorubicin-treated rats,” Chinese Journal of Integrative Medicine, vol. 20, no. 1, pp. 43–48, 2014. View at Google Scholar
  40. Y. Chen, Z. Li, F. Gao, Y. Zhang, H. Sun, and P. Li, “Effects of combined Chinese drugs and chemotherapy in treating advanced non-small cell lung cancer,” Chinese Journal of Integrative Medicine, vol. 15, no. 6, pp. 415–419, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. A. Y. Yan, S. J. Guo, Y. J. Yi et al., “Effect of Shengmai injection “Sandwich” infusion to prevent patients with chemotherapy induced phlebitis,” Chinese Nursing Research, vol. 18, no. 20, pp. 1859–1860, 2004. View at Google Scholar
  42. Z. Zhao, Z. J. Liao, and X. H. Zhao, “The clinic research of the effect of SHENG MAI injection combined with the chemotherapy in the elderly patients with advanced gastric cancer,” Journal of Mordern Oncology, vol. 13, no. 3, pp. 387–388, 2005. View at Google Scholar
  43. L. C. Lo, C. Y. Chen, S. T. Chen, H. C. Chen, T. C. Lee, and C. S. Chang, “Therapeutic efficacy of traditional Chinese medicine, Shen-Mai San, in cancer patients undergoing chemotherapy or radiotherapy: study protocol for randomized, double-blind, placebo-controlled trial,” Trials, vol. 13, article 232, 2012. View at Google Scholar
  44. J. W. Liu, L. X. Sun, Y. Zhao et al., “Clinical phase II study on immunoimprovement of patients with breast cancer treated by Shengyi capsule,” Chinese Journal of Clinical Oncology, vol. 27, no. 7, pp. 534–544, 2000. View at Google Scholar
  45. Y. Sun, H. Zhu, Y. Zhu et al., “A randomized, prospective, multi-centre clinical trial of NP regimen (vinorelbine+cisplatin) plus Gensing Rg3 in the treatment of advanced non-small cell lung cancer patients,” Chinese Journal of Lung Cancer, vol. 9, no. 3, pp. 254–258, 2006. View at Google Scholar · View at Scopus
  46. J. Huang, Y. Sun, Q. Fan, and Y. Zhang, “Efficacy of Shenyi Capsule combined with gemcitabine plus cisplatin in treatment of advanced esophageal cancer: a randomized controlled trial,” Journal of Chinese Integrative Medicine, vol. 7, no. 11, pp. 1047–1051, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. J. T. Coon and E. Ernst, “Panax ginseng: a systematic review of adverse effects and drug interactions,” Drug Safety, vol. 25, no. 5, pp. 323–344, 2002. View at Google Scholar · View at Scopus
  48. L. Qi, C. Wang, G. Du, Z. Zhang, T. Calway, and C. Yuan, “Metabolism of ginseng and its interactions with drugs,” Current Drug Metabolism, vol. 12, no. 9, pp. 818–822, 2011. View at Google Scholar · View at Scopus
  49. D. G. Popovich, C. R. Yeo, and W. Zhang, “Ginsenosides derived from Asian (Panax ginseng), American ginseng (Panax quinquefolius) and potential cytoactivity,” International Journal of Biomedical and Pharmaceutical Sciences, vol. 6, no. 1, pp. 56–62, 2012. View at Google Scholar
  50. T. K. Yun, “Brief introduction of Panax ginseng C.A. Meyer,” Journal of Korean Medical Science, vol. 16, supplement, pp. S3–S5, 2001. View at Google Scholar · View at Scopus
  51. T. Yun, “Panax ginseng—a non-organ-specific cancer preventive?” The Lancet Oncology, vol. 2, no. 1, pp. 49–55, 2001. View at Publisher · View at Google Scholar · View at Scopus
  52. H. R. Shin, J. Y. Kim, T. K. Yun, G. Morgan, and H. Vainio, “The cancer-preventive potential of Panax ginseng: a review of human and experimental evidence,” Cancer Causes and Control, vol. 11, no. 6, pp. 565–576, 2000. View at Publisher · View at Google Scholar · View at Scopus
  53. S. Kang and H. Min, “Ginseng, the “immunity boost”: the effects of Panax ginseng on immune system,” Journal of Ginseng Research, vol. 36, no. 4, pp. 354–368, 2012. View at Google Scholar
  54. S. Lim, C. Cho, U. Choi, and Y. Kim, “Antioxidant activity and ginsenoside pattern of fermented white ginseng,” Journal of Ginseng Research, vol. 34, no. 3, pp. 168–174, 2010. View at Publisher · View at Google Scholar · View at Scopus
  55. M. R. Harkey, G. L. Henderson, M. E. Gershwin, J. S. Stern, and R. M. Hackman, “Variability in commercial ginseng products: an analysis of 25 preparations,” American Journal of Clinical Nutrition, vol. 73, no. 6, pp. 1101–1106, 2001. View at Google Scholar · View at Scopus
  56. M. Mizuno, J. Yamada, H. Terai, N. Kozukue, Y. S. Lee, and H. Tsuchida, “Differences in immunomodulating effects between wild and cultured Panax ginseng,” Biochemical and Biophysical Research Communications, vol. 200, no. 3, pp. 1672–1678, 1994. View at Publisher · View at Google Scholar · View at Scopus
  57. X. Zhang, L. Yu, H. Bi et al., “Total fractionation and characterization of the water-soluble polysaccharides isolated from Panax ginseng C. A. Meyer,” Carbohydrate Polymers, vol. 77, no. 3, pp. 544–552, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. X. G. Gao, Y. Zhi, L. Sun et al., “The inhibitory effects of a rhamnogalacturonan I, (RG-I) domain from ginseng pectin on galectin-3 and its structure-activity relationship,” The Journal of Biological Chemistry, vol. 288, no. 47, pp. 33953–33965, 2013. View at Google Scholar
  59. Y. Chu, H. C. Zhang, S. M. Li et al., “Determination of ginsenoside Rc in rat plasma by LC-MS/MS and its application to a pharmacokinetic study,” Journal of Chromatography B: analytical Technologies in the Biomedical and Life Sciences, vol. 919-920, pp. 75–78, 2013. View at Google Scholar
  60. C. Lv, Q. Li, Y. Zhang et al., “A UFLC-MS/MS method with a switching ionization mode for simultaneous quantitation of polygalaxanthone III, four ginsenosides and tumulosic acid in rat plasma: application to a comparative pharmacokinetic study in normal and Alzheimer's disease rats,” Journal of Mass Spectrometry, vol. 48, no. 8, pp. 904–913, 2013. View at Google Scholar
  61. A. Sparreboom, M. C. Cox, M. R. Acharya, and W. D. Figg, “Herbal remedies in the United States: potential adverse interactions with anticancer agents,” Journal of Clinical Oncology, vol. 22, no. 12, pp. 2489–2503, 2004. View at Publisher · View at Google Scholar · View at Scopus
  62. B. X. Wang, J. C. Cui, and A. J. Liu, “The action of ginsenosides extracted from the stems and leaves of Panax ginseng in promoting animal growth,” Acta Pharmaceutica Sinica, vol. 17, no. 12, pp. 899–904, 1982. View at Google Scholar · View at Scopus
  63. S. Helms, “Cancer prevention and therapeutics: Panax ginseng,” Alternative Medicine Review, vol. 9, no. 3, pp. 259–274, 2004. View at Google Scholar · View at Scopus